<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DDI-DrugBank.d82">
    <sentence id="DDI-DrugBank.d82.s0" text="In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.">
        <entity charOffset="31-42" id="DDI-DrugBank.d82.s0.e0" text="indomethacin" type="drug"/>
        <entity charOffset="67-76" id="DDI-DrugBank.d82.s0.e1" text="diflunisal" type="drug"/>
        <entity charOffset="157-168" id="DDI-DrugBank.d82.s0.e2" text="indomethacin" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s0.e0" e2="DDI-DrugBank.d82.s0.e1" id="DDI-DrugBank.d82.s0.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s0.e0" e2="DDI-DrugBank.d82.s0.e2" id="DDI-DrugBank.d82.s0.p1"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s0.e1" e2="DDI-DrugBank.d82.s0.e2" id="DDI-DrugBank.d82.s0.p2" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s1" text="In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.">
        <entity charOffset="34-40" id="DDI-DrugBank.d82.s1.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="46-55" id="DDI-DrugBank.d82.s1.e1" text="diflunisal" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s1.e0" e2="DDI-DrugBank.d82.s1.e1" id="DDI-DrugBank.d82.s1.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s2" text="Therefore, diflunisal and INDOCIN should not be used concomitantly.">
        <entity charOffset="11-20" id="DDI-DrugBank.d82.s2.e0" text="diflunisal" type="drug"/>
        <entity charOffset="26-32" id="DDI-DrugBank.d82.s2.e1" text="INDOCIN" type="brand"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s2.e0" e2="DDI-DrugBank.d82.s2.e1" id="DDI-DrugBank.d82.s2.p0" type="advise"/>
    <negationtags>Therefore, diflunisal and INDOCIN should &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; be used concomitantly. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d82.s3" text="In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.">
        <entity charOffset="97-103" id="DDI-DrugBank.d82.s3.e0" text="aspirin" type="brand"/>
        <entity charOffset="123-134" id="DDI-DrugBank.d82.s3.e1" text="indomethacin" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s3.e0" e2="DDI-DrugBank.d82.s3.e1" id="DDI-DrugBank.d82.s3.p0" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s4" text="The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.">
        <entity charOffset="23-29" id="DDI-DrugBank.d82.s4.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="42-47" id="DDI-DrugBank.d82.s4.e1" text="NSAIDs" type="group"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s4.e0" e2="DDI-DrugBank.d82.s4.e1" id="DDI-DrugBank.d82.s4.p0" type="advise"/>
    <negationtags>The concomitant use of INDOCIN with other NSAIDs is &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d82.s5" text="Clinical studies have shown that INDOCIN does not influence the hypoprothrombinemia produced by anticoagulants.">
        <entity charOffset="33-39" id="DDI-DrugBank.d82.s5.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="96-109" id="DDI-DrugBank.d82.s5.e1" text="anticoagulants" type="group"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s5.e0" e2="DDI-DrugBank.d82.s5.e1" id="DDI-DrugBank.d82.s5.p0"/>
    <negationtags>Clinical studies have shown that INDOCIN does &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; influence the hypoprothrombinemia produced by anticoagulants. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d82.s6" text="However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.">
        <entity charOffset="45-51" id="DDI-DrugBank.d82.s6.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="95-107" id="DDI-DrugBank.d82.s6.e1" text="anticoagulant" type="group"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s6.e0" e2="DDI-DrugBank.d82.s6.e1" id="DDI-DrugBank.d82.s6.p0" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s7" text="In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.">
        <entity charOffset="99-112" id="DDI-DrugBank.d82.s7.e0" text="anticoagulants" type="group"/>
        <entity charOffset="118-124" id="DDI-DrugBank.d82.s7.e1" text="INDOCIN" type="brand"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s7.e0" e2="DDI-DrugBank.d82.s7.e1" id="DDI-DrugBank.d82.s7.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s8" text="Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.">
        <entity charOffset="33-39" id="DDI-DrugBank.d82.s8.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="45-58" id="DDI-DrugBank.d82.s8.e1" text="anticoagulants" type="group"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s8.e0" e2="DDI-DrugBank.d82.s8.e1" id="DDI-DrugBank.d82.s8.p0" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s9" text="When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.">
        <entity charOffset="5-11" id="DDI-DrugBank.d82.s9.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="44-53" id="DDI-DrugBank.d82.s9.e1" text="probenecid" type="drug"/>
        <entity charOffset="77-88" id="DDI-DrugBank.d82.s9.e2" text="indomethacin" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s9.e0" e2="DDI-DrugBank.d82.s9.e1" id="DDI-DrugBank.d82.s9.p0" type="mechanism"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s9.e0" e2="DDI-DrugBank.d82.s9.e2" id="DDI-DrugBank.d82.s9.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s9.e1" e2="DDI-DrugBank.d82.s9.e2" id="DDI-DrugBank.d82.s9.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s10" text="Therefore, a lower total daily dosage of INDOCIN may produce a satisfactory therapeutic effect.">
        <entity charOffset="41-47" id="DDI-DrugBank.d82.s10.e0" text="INDOCIN" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s11" text="When increases in the dose of INDOCIN are made, they should be made carefully and in small increments.">
        <entity charOffset="30-36" id="DDI-DrugBank.d82.s11.e0" text="INDOCIN" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s12" text="Caution should be used if INDOCIN is administered simultaneously with methotrexate.">
        <entity charOffset="26-32" id="DDI-DrugBank.d82.s12.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="70-81" id="DDI-DrugBank.d82.s12.e1" text="methotrexate" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s12.e0" e2="DDI-DrugBank.d82.s12.e1" id="DDI-DrugBank.d82.s12.p0" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s13" text="INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.">
        <entity charOffset="0-6" id="DDI-DrugBank.d82.s13.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="63-74" id="DDI-DrugBank.d82.s13.e1" text="methotrexate" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s13.e0" e2="DDI-DrugBank.d82.s13.e1" id="DDI-DrugBank.d82.s13.p0" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s14" text="Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.">
        <entity charOffset="18-54" id="DDI-DrugBank.d82.s14.e0" text="non-steroidal anti-inflammatory drugs" type="group"/>
        <entity charOffset="75-86" id="DDI-DrugBank.d82.s14.e1" text="cyclosporine" type="drug"/>
        <entity charOffset="128-139" id="DDI-DrugBank.d82.s14.e2" text="cyclosporine" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s14.e0" e2="DDI-DrugBank.d82.s14.e1" id="DDI-DrugBank.d82.s14.p0" type="effect"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s14.e0" e2="DDI-DrugBank.d82.s14.e2" id="DDI-DrugBank.d82.s14.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s14.e1" e2="DDI-DrugBank.d82.s14.e2" id="DDI-DrugBank.d82.s14.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s15" text="NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.">
        <entity charOffset="0-5" id="DDI-DrugBank.d82.s15.e0" text="NSAIDs" type="group"/>
        <entity charOffset="54-65" id="DDI-DrugBank.d82.s15.e1" text="cyclosporine" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s15.e0" e2="DDI-DrugBank.d82.s15.e1" id="DDI-DrugBank.d82.s15.p0" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s16" text="Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.">
        <entity charOffset="9-15" id="DDI-DrugBank.d82.s16.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="81-87" id="DDI-DrugBank.d82.s16.e1" text="lithium" type="drug"/>
        <entity charOffset="112-118" id="DDI-DrugBank.d82.s16.e2" text="lithium" type="drug"/>
        <entity charOffset="199-205" id="DDI-DrugBank.d82.s16.e3" text="lithium" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s16.e0" e2="DDI-DrugBank.d82.s16.e1" id="DDI-DrugBank.d82.s16.p0" type="mechanism"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s16.e0" e2="DDI-DrugBank.d82.s16.e2" id="DDI-DrugBank.d82.s16.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s16.e0" e2="DDI-DrugBank.d82.s16.e3" id="DDI-DrugBank.d82.s16.p2"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s16.e1" e2="DDI-DrugBank.d82.s16.e2" id="DDI-DrugBank.d82.s16.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s16.e1" e2="DDI-DrugBank.d82.s16.e3" id="DDI-DrugBank.d82.s16.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s16.e2" e2="DDI-DrugBank.d82.s16.e3" id="DDI-DrugBank.d82.s16.p5"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s17" text="This effect has been attributed to inhibition of prostaglandin synthesis."/>
    <sentence id="DDI-DrugBank.d82.s18" text="As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.">
        <entity charOffset="23-29" id="DDI-DrugBank.d82.s18.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="35-41" id="DDI-DrugBank.d82.s18.e1" text="lithium" type="drug"/>
        <entity charOffset="122-128" id="DDI-DrugBank.d82.s18.e2" text="lithium" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s18.e0" e2="DDI-DrugBank.d82.s18.e1" id="DDI-DrugBank.d82.s18.p0" type="advise"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s18.e0" e2="DDI-DrugBank.d82.s18.e2" id="DDI-DrugBank.d82.s18.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s18.e1" e2="DDI-DrugBank.d82.s18.e2" id="DDI-DrugBank.d82.s18.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s19" text="(Read circulars for lithium preparations before use of such concomitant therapy.)">
        <entity charOffset="20-26" id="DDI-DrugBank.d82.s19.e0" text="lithium" type="drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s20" text="In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment.">
        <entity charOffset="47-53" id="DDI-DrugBank.d82.s20.e0" text="lithium" type="drug"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s21" text="INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.">
        <entity charOffset="0-6" id="DDI-DrugBank.d82.s21.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="33-39" id="DDI-DrugBank.d82.s21.e1" text="digoxin" type="drug"/>
        <entity charOffset="124-130" id="DDI-DrugBank.d82.s21.e2" text="digoxin" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s21.e0" e2="DDI-DrugBank.d82.s21.e1" id="DDI-DrugBank.d82.s21.p0" type="mechanism"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s21.e0" e2="DDI-DrugBank.d82.s21.e2" id="DDI-DrugBank.d82.s21.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s21.e1" e2="DDI-DrugBank.d82.s21.e2" id="DDI-DrugBank.d82.s21.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s22" text="Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.">
        <entity charOffset="16-22" id="DDI-DrugBank.d82.s22.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="28-34" id="DDI-DrugBank.d82.s22.e1" text="digoxin" type="drug"/>
        <entity charOffset="66-72" id="DDI-DrugBank.d82.s22.e2" text="digoxin" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s22.e0" e2="DDI-DrugBank.d82.s22.e1" id="DDI-DrugBank.d82.s22.p0" type="advise"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s22.e0" e2="DDI-DrugBank.d82.s22.e2" id="DDI-DrugBank.d82.s22.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s22.e1" e2="DDI-DrugBank.d82.s22.e2" id="DDI-DrugBank.d82.s22.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s23" text="In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.">
        <entity charOffset="40-46" id="DDI-DrugBank.d82.s23.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="118-121;156-164" id="DDI-DrugBank.d82.s23.e1" text="loop diuretics" type="group"/>
        <entity charOffset="124-140;156-164" id="DDI-DrugBank.d82.s23.e2" text="potassium-sparing diuretics" type="group"/>
        <entity charOffset="147-164" id="DDI-DrugBank.d82.s23.e3" text="thiazide diuretics" type="group"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s23.e0" e2="DDI-DrugBank.d82.s23.e1" id="DDI-DrugBank.d82.s23.p0" type="effect"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s23.e0" e2="DDI-DrugBank.d82.s23.e2" id="DDI-DrugBank.d82.s23.p1" type="effect"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s23.e0" e2="DDI-DrugBank.d82.s23.e3" id="DDI-DrugBank.d82.s23.p2" type="effect"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s23.e1" e2="DDI-DrugBank.d82.s23.e2" id="DDI-DrugBank.d82.s23.p3"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s23.e1" e2="DDI-DrugBank.d82.s23.e3" id="DDI-DrugBank.d82.s23.p4"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s23.e2" e2="DDI-DrugBank.d82.s23.e3" id="DDI-DrugBank.d82.s23.p5"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s24" text="Therefore, when INDOCIN and INDOCIN.">
        <entity charOffset="16-22" id="DDI-DrugBank.d82.s24.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="28-34" id="DDI-DrugBank.d82.s24.e1" text="INDOCIN" type="brand"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s24.e0" e2="DDI-DrugBank.d82.s24.e1" id="DDI-DrugBank.d82.s24.p0"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s25" text="(Indomethacin) diuretics are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.">
        <entity charOffset="1-12" id="DDI-DrugBank.d82.s25.e0" text="Indomethacin" type="drug"/>
        <entity charOffset="15-23" id="DDI-DrugBank.d82.s25.e1" text="diuretics" type="group"/>
        <entity charOffset="130-137" id="DDI-DrugBank.d82.s25.e2" text="diuretic" type="group"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s25.e0" e2="DDI-DrugBank.d82.s25.e1" id="DDI-DrugBank.d82.s25.p0"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s25.e0" e2="DDI-DrugBank.d82.s25.e2" id="DDI-DrugBank.d82.s25.p1"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s25.e1" e2="DDI-DrugBank.d82.s25.e2" id="DDI-DrugBank.d82.s25.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s26" text="INDOCIN reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or volume depletion.">
        <entity charOffset="0-6" id="DDI-DrugBank.d82.s26.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="97-106" id="DDI-DrugBank.d82.s26.e1" text="furosemide" type="drug"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s26.e0" e2="DDI-DrugBank.d82.s26.e1" id="DDI-DrugBank.d82.s26.p0"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s27" text="These facts should be considered when evaluating plasma renin activity in hypertensive patients."/>
    <sentence id="DDI-DrugBank.d82.s28" text="It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.">
        <entity charOffset="42-52" id="DDI-DrugBank.d82.s28.e0" text="triamterene" type="drug"/>
        <entity charOffset="83-89" id="DDI-DrugBank.d82.s28.e1" text="INDOCIN" type="brand"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s28.e0" e2="DDI-DrugBank.d82.s28.e1" id="DDI-DrugBank.d82.s28.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s29" text="INDOCIN and triamterene should not be administered together.">
        <entity charOffset="0-6" id="DDI-DrugBank.d82.s29.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="12-22" id="DDI-DrugBank.d82.s29.e1" text="triamterene" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s29.e0" e2="DDI-DrugBank.d82.s29.e1" id="DDI-DrugBank.d82.s29.p0" type="advise"/>
    <negationtags>INDOCIN and triamterene should &lt;scope&gt; &lt;cue&gt; not &lt;/cue&gt; be administered together. &lt;/scope&gt;</negationtags></sentence>
    <sentence id="DDI-DrugBank.d82.s30" text="INDOCIN and potassium-sparing diuretics each may be associated with increased serum potassium levels.">
        <entity charOffset="0-6" id="DDI-DrugBank.d82.s30.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="12-38" id="DDI-DrugBank.d82.s30.e1" text="potassium-sparing diuretics" type="group"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s30.e0" e2="DDI-DrugBank.d82.s30.e1" id="DDI-DrugBank.d82.s30.p0"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s31" text="The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.">
        <entity charOffset="25-31" id="DDI-DrugBank.d82.s31.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="37-63" id="DDI-DrugBank.d82.s31.e1" text="potassium-sparing diuretics" type="group"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s31.e0" e2="DDI-DrugBank.d82.s31.e1" id="DDI-DrugBank.d82.s31.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s32" text="Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.">
        <entity charOffset="37-45" id="DDI-DrugBank.d82.s32.e0" text="diuretics" type="group"/>
        <entity charOffset="152-158" id="DDI-DrugBank.d82.s32.e1" text="INDOCIN" type="brand"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s32.e0" e2="DDI-DrugBank.d82.s32.e1" id="DDI-DrugBank.d82.s32.p0" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s33" text="Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.">
        <entity charOffset="43-75" id="DDI-DrugBank.d82.s33.e0" text="beta-adrenoceptor blocking agents" type="group"/>
        <entity charOffset="80-115" id="DDI-DrugBank.d82.s33.e1" text="non-steroidal antiinflammatory drugs" type="group"/>
        <entity charOffset="127-133" id="DDI-DrugBank.d82.s33.e2" text="INDOCIN" type="brand"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s33.e0" e2="DDI-DrugBank.d82.s33.e1" id="DDI-DrugBank.d82.s33.p0" type="effect"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s33.e0" e2="DDI-DrugBank.d82.s33.e2" id="DDI-DrugBank.d82.s33.p1" type="effect"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s33.e1" e2="DDI-DrugBank.d82.s33.e2" id="DDI-DrugBank.d82.s33.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s34" text="Therefore, when using these blocking agents to treat hypertension, patients should be observed carefully in order to confirm that the desired therapeutic effect has been obtained."/>
    <sentence id="DDI-DrugBank.d82.s35" text="INDOCIN can reduce the antihypertensive effects of captopril and losartan.">
        <entity charOffset="0-6" id="DDI-DrugBank.d82.s35.e0" text="INDOCIN" type="brand"/>
        <entity charOffset="51-59" id="DDI-DrugBank.d82.s35.e1" text="captopril" type="drug"/>
        <entity charOffset="65-72" id="DDI-DrugBank.d82.s35.e2" text="losartan" type="drug"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s35.e0" e2="DDI-DrugBank.d82.s35.e1" id="DDI-DrugBank.d82.s35.p0" type="effect"/>
        <pair ddi="true" e1="DDI-DrugBank.d82.s35.e0" e2="DDI-DrugBank.d82.s35.e2" id="DDI-DrugBank.d82.s35.p1" type="effect"/>
        <pair ddi="false" e1="DDI-DrugBank.d82.s35.e1" e2="DDI-DrugBank.d82.s35.e2" id="DDI-DrugBank.d82.s35.p2"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s36" text="False-negative results in the dexamethasone suppression test (DST) in patients being treated with INDOCIN have been reported.">
        <entity charOffset="98-104" id="DDI-DrugBank.d82.s36.e0" text="INDOCIN" type="brand"/>
    </sentence>
    <sentence id="DDI-DrugBank.d82.s37" text="Thus, results of the DST should be interpreted with caution in these patients."/>
</document>